Omeros Corporation (OMER) was Reiterated by Maxim Group to “Buy” while Lowering the Price Target of the company shares to $ 19 from a previous price target of $30 . Maxim Group advised their investors in a research report released on Aug 10, 2016.
Many Wall Street Analysts have commented on Omeros Corporation. Maxim Group Initiated Omeros Corporation on Jun 3, 2016 to “Buy”, Price Target of the shares are set at $21.Cantor Fitzgerald Initiated Omeros Corporation on Jun 3, 2016 to “Buy”, Price Target of the shares are set at $21.
On the company’s financial health, Omeros Corporation reported $-0.24 EPS for the quarter, beating the analyst consensus estimate by $ 0.25 according to the earnings call on Aug 9, 2016. Analyst had a consensus of $-0.49. The company had revenue of $10.00 million for the quarter, compared to analysts expectations of $9.44 million. The company’s revenue was up 212.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.44 EPS.
Omeros Corporation (OMER) witnessed a volatile trading activity on Monday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $12.51 and reached the intraday high at $12.59. The bulls started the profit booking and pushed the shares to intraday low of $12.28. The trading session was marked by a volume range of 1,74,322 shares exchanging hands. The 52-week high of the shares is $30.23 and the 52-week low is $8.9. The market cap of the company stands at $489 M and there are 3,91,35,054 shares in public circulation.
In a different news, on Jul 15, 2016, Marcia S. Kelbon (VP Patent and General Counsel) sold 15,900 shares at $11.50 per share price. According to the SEC, on Nov 20, 2015, Thomas J. Cable (director) sold 2,000 shares at $13.73 per share price. On Sep 8, 2015, Peter A Md Demopulos (director) purchased 3,962 shares at $12.68 per share price, according to the Form-4 filing with the securities and exchange commission.
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation coagulopathies and disorders of the central nervous system. Its marketed drug product Omidria is approved in the United States for use during cataract surgery or intraocular lens (IOL) which is replacement surgery to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. Omidria is derived from its PharmacoSurgery platform which is for patients undergoing ophthalmological arthroscopic urological and other surgical procedures. It also has six clinical-stage development programs in its pipeline which includes a group of preclinical programs as well as two additional platforms: one capable of unlocking new G protein-coupled receptor drug targets and the other used to generate antibodies.